Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 73.45
-0.957 %
$ 11.6 B
Market Cap
-9.55
P/E
1. INTRINSIC VALUE
Balance Sheet
Illumina, Inc.
| Current Assets | 2.75 B |
| Cash & Short-Term Investments | 1.22 B |
| Receivables | 735 M |
| Other Current Assets | 791 M |
| Non-Current Assets | 3.56 B |
| Long-Term Investments | 0 |
| PP&E | 1.23 B |
| Other Non-Current Assets | 2.32 B |
| Current Liabilities | 1.55 B |
| Accounts Payable | 221 M |
| Short-Term Debt | 499 M |
| Other Current Liabilities | 827 M |
| Non-Current Liabilities | 2.38 B |
| Long-Term Debt | 2.04 B |
| Other Non-Current Liabilities | 339 M |
EFFICIENCY
Earnings Waterfall
Illumina, Inc.
| Revenue | 4.37 B |
| Cost Of Revenue | 1.51 B |
| Gross Profit | 2.86 B |
| Operating Expenses | 3.69 B |
| Operating Income | -833 M |
| Other Expenses | 390 M |
| Net Income | -1.22 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Illumina, Inc.
| Net Income | -1.22 B |
| Depreciation & Amortization | 354 M |
| Capital Expenditures | -128 M |
| Stock-Based Compensation | 370 M |
| Change in Working Capital | -483 M |
| Others | 1.45 B |
| Free Cash Flow | 709 M |
Wall Street Analysts Price Targets
Illumina, Inc.
Wall Street analysts predict an average 1-year price target for ILMN of $140 , with forecasts ranging from
a
low of
$58 to a high of $200 .
ILMN Lowest Price Target
Wall Street Target
58 USD
-21.03%
ILMN Average Price Target
Wall Street Target
140 USD
89.93%
ILMN Highest Price Target
Wall Street Target
200 USD
172.29%
4. DIVIDEND
ANALYSIS
ILMN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Illumina, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why Illumina (ILMN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
- 2 weeks ago
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
cnbc.com
- 3 weeks ago
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years.
seekingalpha.com
- 3 weeks ago
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board.
prnewswire.com
- 3 weeks ago
Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
reuters.com
- 3 weeks ago
Activist Investor Meister to Join Illumina's Board
Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.
wsj.com
- 3 weeks ago
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
zacks.com
- 4 weeks ago
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO , March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development.
prnewswire.com
- 1 month ago
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
- 1 month ago
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
zacks.com
- 1 month ago
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.
reuters.com
- 1 month ago
Illumina addresses recent developments in China
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO , March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export sequencing instruments into China. Illumina respects MOFCOM's decision and will continue to comply with all applicable laws and regulations wherever the company operates.
prnewswire.com
- 1 month ago
8. Profile
Summary
Illumina, Inc. ILMN
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 11.6 B
Dividend Yield
0.00%
Description
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Contact
5200 Illumina Way, San Diego, CA, 92122
https://www.illumina.com
IPO
Date
July 28, 2000
Employees
8970
Officers
Ms. Carissa L. Rollins
Chief Information Officer
Mr. Jacob Thaysen Ph.D.
Chief Executive Officer & Director